Welcome
Support Centre
06 January 2009 
ISRCTN Register - International Standard Randomized Controlled Trial Number
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   UKCTG  |   links  |   information  |   press
Find trials
ISRCTN Register
tips on searching

Registration
New application
Updating record

Information
introduction
governing board
ISRCTN FAQs
data set
letter of agreement
request information
guidance notes

[ Print-friendly version ]
Serotonin sensitivity in insomnia: a placebo-controlled crossover study of sleep after 5HT2 blockade in primary insomnia
ISRCTN ISRCTN38174888
ClinicalTrials.gov identifier
Public title Serotonin sensitivity in insomnia: a placebo-controlled crossover study of sleep after 5HT2 blockade in primary insomnia
Scientific title
Acronym N/A
Serial number at source N0038183440
Study hypothesis Does Trazodone improve sleep in primary insomnia?
Ethics approval Added September 2008: Approved 21/04/2006 by Bath Research Ethics Committee, REC number 06/Q2001/32.
Study design Randomised, double-blind, placebo-controlled crossover study
Countries of recruitment United Kingdom
Disease/condition/study domain Nervous System Diseases: Primary insomnia
Participants - inclusion criteria 1. Adults referred to Psychopharmacology Unit Clinic 7, Bristol Royal Infirmary with psycho-physiological insomnia
2. Complaint of poor sleep with daytime consequences
Participants - exclusion criteria 1. Taking psychotropic medication
2. Total sleep time (subjective) < 6.5 hours
3. Current psychiatric disorder
Anticipated start date 28/04/2006
Anticipated end date 31/01/2009
Status of trial Ongoing
Patient information material Not available in web format, please use the contact details below to request a patient information sheet
Target number of participants 12 insomnia patients
Interventions Trazodone vs placebo.
Overnight sleep patterns recorded and compared, after either placebo or trazodone 100mg. Each patient has screening visit and 2 overnight sleep recordings at home a week apart, plus an end-of study visit.
Primary outcome measure(s) Sleep efficiency: % Total Sleep Time / Staging Time.
Secondary outcome measure(s) 1. Daily symptom report (DSR)
2. Total sleep time (TST)
3. Number of awakenings
4. Wake Time After Sleep Onset (WASO)
5. Time spent in stages 1 to 4 and rapid eye movement (REM), %TST spent in each stage
6. REM onset latency
7. Sleep onset Latency (SOL), slow wave activity
8. Leeds Sleep Evaluation Questionnaire.
Sources of funding Avon and Wiltshire Mental Health Partnership NHS Trust (UK)
AWP Partnership Mental Health NHS Trust R&D Project grant
NHS R&D Support Funding
Trial website
Publications
Contact name Dr  Sue  Wilson
  Address University of Bristol
Dorothy Hodgkin Building
Whitson Street
  City/town Bristol
  Zip/Postcode BS1 3NY
  Country United Kingdom
  Tel +44 0117 331 3172
  Fax +44 0117 331 3180
  Email sue.wilson@bris.ac.uk
Sponsor Record Provided by the NHSTCT Register - 2007 Update - Department of Health
  Address The Department of Health, Richmond House, 79 Whitehall
  City/town London
  Zip/Postcode SW1A 2NL
  Country United Kingdom
  Tel +44 (0)20 7307 2622
  Fax +44
  Email dhmail@doh.gsi.org.uk
  Sponsor website: http://www.dh.gov.uk/Home/fs/en
Date applied 28/09/2007
Last edited 10/09/2008
Date ISRCTN assigned 28/09/2007
Submit your trial protocol Top studies in medical research Submit to Trials journal
© ISRCTN


BioMed Central